Blog

Boston Scientific Expands Oncology Portfolio with Acquisition of Intera Oncology

Boston Scientific/X

Nov 27, 2024, 18:01

Boston Scientific Expands Oncology Portfolio with Acquisition of Intera Oncology

Boston Scientific has announced its agreement to acquire Intera Oncology® Inc., a company known for its hepatic artery infusion (HAI) pump technology used in the targeted treatment of primary and secondary liver cancers.

This acquisition is part of Boston Scientific’s ongoing effort to broaden its oncology portfolio and deliver innovative solutions for patients requiring specialized care.

The HAI pump developed by Intera Oncology provides a targeted approach to chemotherapy, offering benefits such as localized drug delivery and reduced systemic exposure compared to traditional methods. This technology is particularly impactful for patients with unresectable liver cancer or metastatic disease, improving treatment outcomes and offering a significant advancement in therapeutic strategies.

The deal is expected to enhance the reach of this technology, combining Boston Scientific’s extensive global infrastructure with Intera Oncology’s specialized innovation. By integrating these systems, the acquisition aims to improve healthcare provider access to cutting-edge treatments, ensuring better care for patients facing complex conditions.

“Liver cancer is a leading cause of cancer-related death, and we are committed to providing meaningful solutions to safely and effectively treat various forms of this disease with minimal systemic side effects and improved outcomes for patients.” – Peter Pattison, president, Interventional Oncology and Embolization, Boston Scientific

About Boston Scientific

Boston Scientific enhances patient lives through cutting-edge medical technologies, addressing critical healthcare needs globally for over 45 years. As a leader in medical innovation, the company delivers high-performance solutions to improve outcomes and reduce healthcare costs.

Boston Scientific Beats Q2 Estimates, Ups Full-Year Guidance - Medical Product Outsourcing

About Intera Oncology® Inc:

Intera Oncology is a Boston-based medical device company dedicated to changing the course of cancer with Hepatic Artery Infusion. Intera Oncology was founded by Jonathan Reis, M.D. and David Dove, M.D. who learned of the pump’s discontinuation from a New York Times article published five years ago.

Intera Oncology - Hepatic Artery Infusion Therapy